Nuclear receptors (NRs) have historically been at the forefront of cancer research, where they are known to act as critical regulators of disease. They also serve as biomarkers for tumour subclassification and targets for hormone therapy. However, most tumour types express extensive repertoires of NRs, whose interactions provide multiple paths for disease progression and offer potentially untapped mechanisms for therapeutic interventions. Recently, next-generation sequencing technologies have provided genome-wide insights into the complex interplay of NR transcriptional networks and their contribution to the development and progression of cancer. These findings have altered the traditional understanding of NR activities in oncogenesis.

核受体（NRs）历史上一直处于癌症研究的最前沿，众所周知，核受体是疾病的关键调节剂。它们还可以作为肿瘤亚分类的生物标志物和激素治疗的靶标。然而，大多数肿瘤类型表达了广泛的NRs，它们的相互作用为疾病发展提供了多种途径，并为治疗干预提供了可能尚未开发的机制。最近，下一代测序技术已经为NR转录网络的复杂相互作用及其对癌症发展和进程的贡献提供了全基因组的见解。这些发现改变了对肿瘤发生中NR活性的传统理解。